A European, Observational, 3-Year Cohort Comparative Study on the Safety of the Fixed Dose Combination Pravastatin 40 mg/Fenofibrate 160 mg vs. Statin Alone in Real Clinical Practice: The POSE Study.

Autor: Papadopoulos N; Saint Luke's Hospital, Thessaloniki, Greece., Arvaniti E; Internal Medicine and Diabetes, General Hospital of Ioannina 'G. Hatzikosta', Ioannina, Greece., Angelopoulos T; Internal Medicine and Diabetes, Iatriko Paleou Falirou, Athens, Greece., Tziomalos K; First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece., Tembra MS; Internal Medicine. Lipid Unit Hospital San Rafael, A Coruña, Spain., Diaz JL; Lipid and Cardiovascular Risk Unit Internal Medicine Complejo Hospitalario Universitario A Coruña, A Coruña, Spain., De Niet S; Clinical Department, Laboratoires SMB, Brussels, Belgium., Da Silva S; Clinical Department, Laboratoires SMB, Brussels, Belgium., Doupis J; Internal Medicine and Diabetes, Iatriko Paleou Falirou, Athens, Greece.
Jazyk: angličtina
Zdroj: Pharmacoepidemiology and drug safety [Pharmacoepidemiol Drug Saf] 2024 Nov; Vol. 33 (11), pp. e70047.
DOI: 10.1002/pds.70047
Abstrakt: Background and Purpose: The aim of the study was to provide valuable real-world long-term safety data of the fixed pravastatin 40 mg/fenofibrate 160 mg combination in comparison of monotherapy with statins of moderate intensity.
Materials and Methods: POSE study was an observational, comparative study conducted in three European countries. Patients treated or planned to be treated with pravastatin 40 mg/fenofibrate 160 mg or with a moderate-intensity statin in monotherapy were assessed over 3 years. The main safety endpoints included the incidence of renal or urinary disorder, musculoskeletal or connective tissue disorder, hepatobiliary disorder and cardiovascular events.
Results: The study included 3075 patients treated for dyslipidaemia, with diabetes mellitus (47%), hypertension (56%) and/or established cardiovascular disease (61%). Over the 3 years of follow-up, the difference in incidence rate of safety events between the pravastatin 40 mg/fenofibrate 160 mg group and the statin group was not statistically significant (RR = 1.366 [95% CI = 0.967-1.929]). The most frequently occurring events were musculoskeletal and connective tissue disorders (AR = 0.030 in the pravastatin 40 mg/fenofibrate 160 mg group and 0.024 in the statin group), renal and urinary disorders (AR = 0.019 vs. 0.016, respectively) and aggravated diabetes mellitus (0.021 vs. 0.014). Most events occurred during the first year, then incidence decreased over the 3-year period. No statistically significant difference was observed between treatment groups regarding the cardiovascular events (RR = 1.209 [95% CI = 0.596-2.453]) and no new signal emerged from the long-term follow-up.
Conclusions: This study demonstrates a reassuring long-term safety profile of the fixed pravastatin 40 mg/fenofibrate 160 mg combination in routine clinical practice, with low and similar incidence of events over the 3 years follow-up compared to a monotherapy with statins of moderate intensity.
(© 2024 The Author(s). Pharmacoepidemiology and Drug Safety published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: